Specific germline polymorphisms or composite haplotypes, in conjunction with tumor features (e.g., sidedness) and molecular profile (e.g., RAS, BRAF, HER2, MSI status, CMS subtype) may serve to inform the selection of mCRC patients to treat with cetuximab and other targeted or immune therapies. Here, BRAF is linked to neoplasm.